Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
130.3 USD | +1.26% | +0.67% | +19.63% |
04:04pm | Merck to present new oncology data | CF |
May. 14 | US FDA declines to approve expanded use of Dynavax's hepatitis B vaccine | RE |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+19.63% | 326B | |
+31.37% | 588B | |
-3.14% | 364B | |
+5.23% | 285B | |
+14.83% | 239B | |
+9.93% | 210B | |
-6.95% | 200B | |
+10.24% | 167B | |
+0.09% | 161B | |
+0.89% | 124B |
- Stock Market
- Equities
- MRK Stock
- News Merck & Co., Inc.
- (MRK) MERCK & CO. Expects Fiscal Year 2024 EPS Range $8.53 - $8.65